Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business update on Monday, August 9, 2021 at 8:30 a.m. ET.
August 3, 2021
· 2 min read